Dr. Silviu Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-12-2024
- Paid Up Capital ₹ 0.10 M
as on 06-12-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2021
- Revenue 70.78%
(FY 2021)
- Profit -44.96%
(FY 2021)
- Ebitda -255.14%
(FY 2021)
- Net Worth -154.25%
(FY 2021)
- Total Assets 13.48%
(FY 2021)
About Dr. Silviu Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Bhise and Trupti Bhise serve as directors at the Company.
- CIN/LLPIN
U24232PN2009PTC134923
- Company No.
134923
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2009
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dr. Silviu Pharmachem Private Limited offer?
Dr. Silviu Pharmachem Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Organic Compounds, Insecticides and Pesticides, Pesticide Intermediate, Industrial Chemicals & Supplies, Fragrance Chemicals, Organic and Inorganic Solvents, Organic Chemicals, Aromatic Hydrocarbon Solvent, Halogenating Agent.
Who are the key members and board of directors at Dr. Silviu Pharmachem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Bhise  | Director | 05-Nov-2009 | Current |
| Trupti Bhise | Director | 05-Nov-2009 | Current |
Financial Performance of Dr. Silviu Pharmachem.
Dr. Silviu Pharmachem Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 70.78% increase. The company also saw a substantial fall in profitability, with a 44.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 154.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Silviu Pharmachem?
In 2021, Dr. Silviu Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr. Silviu Pharmachem?
Unlock and access historical data on people associated with Dr. Silviu Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Silviu Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Silviu Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
